🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06074679
Recruiting Not applicable

Clinical Study of Single Incision Laparoscopic Cholecystectomy in the Treatment of Patients With Acute Cholecystitis

NCT06074679 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Started
2023-10-01
Last updated
2024-11-21

Condition(s) studied

Cholecystectomy, Laparoscopic

Investigational drug(s) / intervention(s)

Open cholecystectomy

Open cholecystectomy: The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.

Study summary

Gallstone is a common disease in China.At present, the prevalence of gallstones in China is 15 %, and about 210 million people are sick. Acute cholecystitis is acute gallbladder inflammation, is one of the main complications of cholelithiasis or gallstones. The removal of gallbladder and gallstones in patients with acute cholecystitis in the presence of biliary pain will prevent the recurrence of gallbladder and reduce the risk of cholecystitis progression. If gallbladder perforation is not treated in time, the mortality rate is 30 %. Acute acalculous cholecystitis without treatment will be life-threatening, with a mortality rate of up to 50 %. At present, the vast majority of patients with acute cholecystitis are treated with 4-hole traditional laparoscopic cholecystectomy and open cholecystectomy. Their postoperative quality of life, pain and scar-related complications, remain major factors for patients.In recent years, with the renewal of the concept of minimally invasive surgery and the continuous advancement of instruments and technology, single-incision laparoscopic cholecystectomy has also maximized the quality of life after surgery and reduced postoperative pain and scar-related complications. At present, there are few reports on randomized controlled clinical trials of SILC in patients with acute cholecystitis, and there is a lack of large sample size studies.Due to the difficulty of SILC operation, the longer learning curve, the different equipment conditions and technical characteristics of each center, and the lack of standardized training, there is no effective consensus on the application indications and operation procedures of SILC in acute cholecystitis surgery. Based on the current status, the purpose of this study was to investigate the effect of SILC on postoperative quality of life, postoperative pain, scar assessment and postoperative complications in patients with acute cholecystitis, so as to propose a standardized single incision laparoscopic operation procedure in the treatment of acute cholecystitis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Acute cholecystitis(GradeⅠ,II) Exclusion Criteria: * Combined with liver cirrhosis (Child grade B and above) * Upper abdominal surgical history; * Changes in surgical plan (conversion to laparotomy,cholangiography, bile duct exploration, bile duct injury repair, abscess clearance, multivisceral resection.) * Patients and their families do not agree with the treatment lost follow-up

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Shexian Branch, Second Affiliated Hospital, School of Medicine, Zhejiang University Huangshan City Anhui Recruiting
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China Hangzhou Zhejiang Recruiting
Changxing Branch, Second Affiliated Hospital, School of Medicine, Zhejiang University Huzhou Zhejiang Recruiting
Suichang Branch, Second Affiliated Hospital, School of Medicine, Zhejiang University Lishui Zhejiang Recruiting
Jiande Branch, Second Affiliated Hospital, School of Medicine, Zhejiang University Meicheng Zhejiang Recruiting

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06074679 on ClinicalTrials.gov ↗ ← All trials in China